eLife SJR and Scopus Metrics: What the Numbers Actually Tell Authors
eLife still carries strong citation signal, but the real submission question is whether your field and career context can read the reviewed-preprint model correctly.
Research Scientist, Neuroscience & Cell Biology
Author context
Works across neuroscience and cell biology, with direct expertise in preparing manuscripts for PNAS, Nature Neuroscience, Neuron, eLife, and Nature Communications.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Quick answer: Scopus-linked metric aggregators still place eLife around an SJR of 3.93, with Q1 standing and strong long-window citation performance. That confirms real scientific visibility. But eLife is no longer a normal accept-reject journal, so the submission decision still depends more on whether you want a reviewed-preprint outcome than on the metric alone.
The core metric picture
Metric | Current read | What it tells you |
|---|---|---|
SJR | ~3.93 | Prestige-weighted citation influence remains strong |
Cites / document (4 years) | ~6.90 | Papers still attract meaningful medium-term attention |
Quartile | Q1 | The journal still sits in an upper-tier biology position |
Category examples | High in neuroscience and broad biochemistry views | Cross-field visibility remains real |
Publishing model | Reviewed preprints with public assessment | The journal now signals differently from a conventional acceptance outcome |
The useful reading is that eLife still matters scientifically, but the metric is no longer enough by itself to tell you whether the journal is strategically right.
What the metrics actually help with
They help answer three practical questions:
- whether the journal still sits in a real citation network
- whether eLife remains visible enough to matter scientifically
- whether the publishing-model change erased the journal's influence
The answer to all three is no: the influence did not disappear. What changed is how the publication outcome gets interpreted by committees, coauthors, and institutions.
What the metrics do not answer
They do not tell you:
- whether your department understands reviewed preprints
- whether your coauthors want public reviews and assessments attached to the work
- whether you need a conventional accepted-article signal for hiring, promotion, or grant review
- whether the manuscript is ready for open scrutiny rather than private reviewer exchange
Those are still the real submission questions.
Why the profile matters for authors
At this SJR level, eLife is still scientifically visible. The citation signal says the journal still publishes papers the field reads and cites.
But the profile now supports a different editorial product:
- transparent peer review
- public editorial assessment
- preprint-native publishing
- strong visibility in open-science-forward communities
That is why eLife is one of the few journals where the metric and the model have to be read together. The SJR still signals influence. It does not restore the old prestige shorthand.
What should drive the submission decision instead
The better question is whether the manuscript belongs in eLife's reviewed-preprint ecosystem.
That is why the better next reads are:
- Is eLife a good journal?
- eLife submission guide
- eLife submission process
- eLife acceptance rate
If the team wants transparent review and a visible public assessment, the metric supports eLife as a real venue. If the team needs a conventional accept-reject prestige signal, the metric does not solve that mismatch.
Practical verdict
eLife still has a strong Scopus-style profile, and that matters. It shows the journal did not become invisible after the publishing-model shift.
But the more important question is still fit. If your field, funder, and career context can read reviewed preprints intelligently, eLife can still be a very strong outcome. If they cannot, the metric is not the deciding issue. The model is. A free Manusights scan is the fastest way to pressure-test that before submission.
- Is eLife a good journal?, Manusights.
Sources
- 1. eLife metrics page, JRank.
- 2. eLife SJR profile, Resurchify.
- 3. Submit your research, eLife.
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- eLife Submission Guide
- Is eLife a Good Journal? Fit Verdict
- How to Avoid Desk Rejection at eLife in 2026
- eLife Submission Process: The Reviewed Preprint Model Explained
- eLife Pre-Submission Checklist: Is Your Paper Ready for the Reviewed Preprint Model?
- eLife Impact Factor 2026: Why It's No Longer Listed
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.